ZNF229

Summary

ZNF229 (zinc finger protein 229, HGNC:13022) is a protein-coding gene on chromosome 19q13.31, encoding Zinc finger protein 229 (Q9UJW7). May be involved in transcriptional regulation.

Predicted to enable DNA binding activity and zinc ion binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 7772 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 5
• Clinical variants (ClinVar): 160 total
• MANE Select transcript: NM_014518

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13022
Approved symbol	ZNF229
Name	zinc finger protein 229
Location	19q13.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000278318
Ensembl biotype	protein_coding
OMIM	620827
Entrez	7772

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000591289, ENST00000592308, ENST00000613197, ENST00000614049, ENST00000620012, ENST00000911243, ENST00000911244

RefSeq mRNA: 2 — MANE Select: NM_014518 NM_001278510, NM_014518

CCDS: CCDS42574, CCDS62706

Canonical transcript exons

ENST00000614049 — 6 exons

Exon	Start	End
ENSE00002864749	44448309	44448472
ENSE00003476853	44447513	44447600
ENSE00003724001	44442814	44443024
ENSE00003739905	44426254	44430542
ENSE00003744596	44432222	44432366
ENSE00003744667	44442563	44442621

Expression profiles

Bgee: expression breadth ubiquitous, 168 present calls, max score 82.97.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.0325 / max 132.9588, expressed in 1241 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181393	4.0325	1241

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.97	gold quality
adrenal tissue	UBERON:0018303	80.32	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.98	gold quality
cortical plate	UBERON:0005343	79.68	gold quality
ventricular zone	UBERON:0003053	79.35	gold quality
ganglionic eminence	UBERON:0004023	78.16	gold quality
islet of Langerhans	UBERON:0000006	77.89	gold quality
secondary oocyte	CL:0000655	76.94	gold quality
stromal cell of endometrium	CL:0002255	74.96	gold quality
pigmented layer of retina	UBERON:0001782	71.60	gold quality
epithelial cell of pancreas	CL:0000083	69.59	gold quality
smooth muscle tissue	UBERON:0001135	69.49	gold quality
germinal epithelium of ovary	UBERON:0001304	69.35	silver quality
left adrenal gland	UBERON:0001234	68.63	gold quality
left adrenal gland cortex	UBERON:0035825	68.60	gold quality
ovary	UBERON:0000992	68.12	gold quality
pancreas	UBERON:0001264	68.03	gold quality
right adrenal gland cortex	UBERON:0035827	68.02	gold quality
left ovary	UBERON:0002119	67.92	gold quality
adrenal gland	UBERON:0002369	67.85	gold quality
right adrenal gland	UBERON:0001233	67.84	gold quality
heart left ventricle	UBERON:0002084	67.69	gold quality
thyroid gland	UBERON:0002046	67.68	gold quality
left lobe of thyroid gland	UBERON:0001120	67.66	gold quality
gall bladder	UBERON:0002110	67.51	gold quality
cardiac ventricle	UBERON:0002082	67.23	gold quality
right lobe of thyroid gland	UBERON:0001119	66.76	gold quality
adrenal cortex	UBERON:0001235	66.72	gold quality
right ovary	UBERON:0002118	66.70	gold quality
heart	UBERON:0000948	66.42	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.71

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

81 targeting ZNF229, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-202-5P	99.78	67.65	991
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-132-3P	99.73	70.56	1424

Cross-species orthologs

0 orthologs

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631)

Protein

Protein identifiers

Zinc finger protein 229 — Q9UJW7 (reviewed: Q9UJW7)

All UniProt accessions (4): Q9UJW7, A0A087WVZ7, A0A087X068, K7EIU9

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9UJW7-1	1	yes
Q9UJW7-2	2

RefSeq proteins (2): NP_001265439, NP_055333* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (28 total): zinc finger region 18, sequence variant 5, chain 1, domain 1, region of interest 1, cross-link 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UJW7-F1	62.77	0.03

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 543

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 60 (showing top): GOZGIT_ESR1_TARGETS_DN, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, KRIEG_HYPOXIA_NOT_VIA_KDM3A, ZNF10_TARGET_GENES, MIR153_5P, MIR548AR_3P, MIR548F_3P, MIR548BC, MIR548AZ_3P, MIR548A_3P, MIR548E_3P, GSE11057_NAIVE_VS_MEMORY_CD4_TCELL_UP, MIR10393_5P, MIR4450, MIR4771

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (4): DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

196 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF229	PDE3B	Q13370	524
ZNF229	OR4F6	Q8NGB9	506
ZNF229	PHYHD1	Q5SRE7	323
ZNF229	TMEM64	Q6YI46	321
ZNF229	DENND4A	Q7Z401	308
ZNF229	OR1M1	Q8NGA1	294
ZNF229	FKBP9	O95302	293
ZNF229	ZNF395	Q9H8N7	274
ZNF229	EBLN2	Q6P2I7	271
ZNF229	OR10K1	Q8NGX5	270
ZNF229	ZNF503	Q96F45	261
ZNF229	TRIM69	Q86WT6	260
ZNF229	FMO2	Q99518	253
ZNF229	FMO4	P31512	253
ZNF229	TFB2M	Q9H5Q4	248
ZNF229	MAMLD1	Q13495	248

IntAct

9 interactions, top by confidence:

A	B	Type	Score
CABP5	ZNF229	psi-mi:“MI:0915”(physical association)	0.560
TPM2	ZNF229	psi-mi:“MI:0915”(physical association)	0.560
M		psi-mi:“MI:0914”(association)	0.350
NDEL1	ZNF229	psi-mi:“MI:0915”(physical association)	0.000
CABP5	ZNF229	psi-mi:“MI:0915”(physical association)	0.000
TPM2	ZNF229	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (5): ZNF229 (Synthetic Lethality), ZNF229 (Two-hybrid), ZNF229 (Two-hybrid), ZNF229 (Affinity Capture-MS), ZNF229 (Affinity Capture-MS)

ESM2 similar proteins: A0A087WUV0, A0JNB1, A2VDP4, B2RUI1, P0CG31, P10072, P17025, P17036, P17097, P18733, P51814, Q08ER8, Q09FC8, Q0VGE8, Q14590, Q15937, Q16600, Q2M3X9, Q4V8A8, Q5CZA5, Q5R8G9, Q5RBX0, Q5VIY5, Q68DI1, Q6J6I6, Q6NX49, Q6P1L6, Q6PG37, Q6ZMS4, Q6ZMW2, Q80YP6, Q86UD4, Q86Y25, Q8IZ26, Q8N184, Q8NB42, Q8NEK5, Q8TAF7, Q8TF47, Q8WXB4

Diamond homologs: A0A1W2PQL4, A0JNB1, A0JPL0, A6NK53, A6QLU5, A6QPT6, A7MBI1, A8MT65, A8MUV8, A8MWA4, B2RXC5, B4DU55, B4DX44, E9PYI1, O14628, O75346, P0CH99, P0CI00, P17014, P17030, P17032, P17098, P51786, P85977, Q02386, Q06730, Q06732, Q0VAW7, Q12901, Q13360, Q14586, Q14588, Q14590, Q16587, Q2M3X9, Q2VY69, Q32M78, Q3ZCX4, Q49AA0, Q4R6J4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

160 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	137
Likely benign	16
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1570 predictions. Top by Δscore:

Variant	Effect	Δscore
19:44432239:CCCA:C	donor_gain	1.0000
19:44432242:A:AC	donor_gain	1.0000
19:44432243:C:CC	donor_gain	1.0000
19:44432255:T:A	donor_gain	1.0000
19:44445081:A:AC	donor_gain	1.0000
19:44445082:C:CC	donor_gain	1.0000
19:44445084:T:TA	donor_gain	1.0000
19:44447508:CTCA:C	donor_loss	1.0000
19:44447509:TCACC:T	donor_loss	1.0000
19:44447510:CACC:C	donor_loss	1.0000
19:44447511:A:AC	donor_gain	1.0000
19:44447511:A:T	donor_loss	1.0000
19:44447512:C:CC	donor_gain	1.0000
19:44447512:C:CG	donor_loss	1.0000
19:44447601:C:CC	acceptor_gain	1.0000
19:44448294:ACACC:A	donor_gain	1.0000
19:44448295:CACCC:C	donor_gain	1.0000
19:44431492:G:A	donor_gain	0.9900
19:44432231:T:TA	donor_gain	0.9900
19:44432251:AGGTT:A	donor_gain	0.9900
19:44432266:T:A	donor_gain	0.9900
19:44432272:A:AC	donor_gain	0.9900
19:44432364:CTC:C	acceptor_gain	0.9900
19:44432367:C:CG	acceptor_loss	0.9900
19:44434581:A:AC	donor_gain	0.9900
19:44434584:A:AC	donor_gain	0.9900
19:44434585:C:CC	donor_gain	0.9900
19:44445088:T:A	donor_gain	0.9900
19:44446830:T:TA	donor_gain	0.9900
19:44447597:AAGCC:A	acceptor_loss	0.9900

AlphaMissense

5508 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:44428450:A:C	F777L	0.998
19:44428450:A:T	F777L	0.998
19:44428452:A:G	F777L	0.998
19:44429539:G:C	F414L	0.998
19:44429539:G:T	F414L	0.998
19:44429541:A:G	F414L	0.998
19:44428702:G:C	F693L	0.997
19:44428702:G:T	F693L	0.997
19:44428704:A:G	F693L	0.997
19:44428786:A:C	F665L	0.997
19:44428786:A:T	F665L	0.997
19:44428788:A:G	F665L	0.997
19:44429038:G:C	F581L	0.997
19:44429038:G:T	F581L	0.997
19:44429040:A:G	F581L	0.997
19:44429623:A:C	F386L	0.997
19:44429623:A:T	F386L	0.997
19:44429625:A:G	F386L	0.997
19:44428618:G:C	F721L	0.996
19:44428618:G:T	F721L	0.996
19:44428620:A:G	F721L	0.996
19:44428870:G:C	F637L	0.996
19:44428870:G:T	F637L	0.996
19:44428872:A:G	F637L	0.996
19:44428954:G:C	F609L	0.996
19:44428954:G:T	F609L	0.996
19:44428956:A:G	F609L	0.996
19:44429122:A:C	F553L	0.996
19:44429122:A:T	F553L	0.996
19:44429124:A:G	F553L	0.996

dbSNP variants (sampled 300 via entrez): RS1000026244 (19:44427171 T>C), RS1000243940 (19:44450390 C>A,T), RS1000354503 (19:44444114 C>A,T), RS1000462616 (19:44437924 G>A), RS1000514520 (19:44438154 T>C), RS1000579822 (19:44449153 A>G), RS1000598469 (19:44450150 C>T), RS1000645684 (19:44436928 T>C), RS1000785708 (19:44448873 G>T), RS1000882736 (19:44437211 T>C), RS1000962016 (19:44430289 C>A), RS1001075164 (19:44431964 C>T), RS1001139940 (19:44425795 C>T), RS1001203539 (19:44427271 G>A), RS1001277375 (19:44434367 T>C)

Disease associations

OMIM: gene MIM:620827 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST005950_15	Body mass index x sex x age interaction (4df test)	2.000000e-10
GCST005951_56	Body mass index	1.000000e-06
GCST005952_8	Body mass index (age>50)	9.000000e-12
GCST005954_4	Body mass index x age interaction	2.000000e-07
GCST009391_1533	Metabolite levels	2.000000e-07

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0009771	methionine measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, decreases expression	1
Decitabine	increases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects methylation	1
Catechin	affects cotreatment, decreases expression	1
Methotrexate	decreases expression	1
Cyclosporine	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety